Arikha Moses
Oprichter bij Galatea Surgical, Inc.
Profiel
Arikha Moses is the founder of Galatea Surgical, Inc. founded in 2011.
Dr. Moses is also the founder of TYRX, Inc. Dr. Moses held former positions as Director-Research & Development at Helix Therapeutics, Inc., Principal at ImmunoGen, Inc., Entrepreneur-in-Residence at The Vertical Group LP from 2010 to 2014, and Vice President at Athena Ventures from 2007 to 2008.
Dr. Moses received an undergraduate degree from Brandeis University and a doctorate degree from Yale University.
Actieve functies van Arikha Moses
Bedrijven | Functie | Begin |
---|---|---|
Galatea Surgical, Inc. | Oprichter | 01-01-2011 |
Eerdere bekende functies van Arikha Moses
Bedrijven | Functie | Einde |
---|---|---|
The Vertical Group LP
The Vertical Group LP Investment ManagersFinance The Vertical Group LP (TVG) is a venture capital firm founded in 1988 by Richard B. Emmitt. The firm is headquartered in Berkeley Heights, New Jersey. | Corporate Officer/Principal | 31-12-2014 |
TYRX, Inc.
TYRX, Inc. Electronic Equipment/InstrumentsElectronic Technology TYRX, Inc. designs and manufactures medical-pharmaceutical combination devices. The firm commercializes implantable combination drug and device products focused on infection control including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs). Its AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including superbugs such as methicillin-resistant S. aureus (MRSA). The company was founded in 1998 by Satish Pulapura and Arikha Moses and is headquartered in Monmouth Junction, NJ. | Oprichter | 01-01-2010 |
Athena Ventures | President | 31-12-2008 |
Helix Therapeutics, Inc.
Helix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Helix Therapeutics is a seed stage company based on technology discovered in the laboratory of Peter Glazer MD/PhD and licensed on a world wide, exclusive basis from Yale University. Targeted DNA modifications can be designed to: correct mutations, leading to restoration of normal function of key gene products, alter levels of gene expression, potentially turning genes on or off, functionally disrupt molecules, such as the CCR5 receptor, which mediates HIV entry into T cells. Through the use of SBIR grants and seed funding, it will advance preclinical projects targeting the human globin gene for applications on sickle cell anemia and beta-thalassemia, the CCR5 receptor for the HIV/AIDS population, and genetic mutations responsible for the liposomal storage disease, Gaucher's. Genetic alteration of stem cells has the potential to dramatically impact the efficacy of stem cell therapy for human disease. Due to the accessibility of HSC without bone marrow transplants, the company is currently focused on blood based genetic diseases. As advances in human stem cell biology are realized, however, it is possible to envision applications in a broad array of human genetic diseases. Moreover, because the DNA modifications introduced to stem cells are stable and heritable; this technology offers the hope of curing certain genetic diseases. Its approach does not rely on viral vectors and corrects the patients own cells, eliminating potential immune reactions. This approach is classified as Cellular Therapy, which provides another level of safety to the patient. | Hoofd Techniek/Wetenschap/O&O | - |
IMMUNOGEN, INC. | Corporate Officer/Principal | - |
Opleiding van Arikha Moses
Brandeis University | Undergraduate Degree |
Yale University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
IMMUNOGEN, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
TYRX, Inc.
TYRX, Inc. Electronic Equipment/InstrumentsElectronic Technology TYRX, Inc. designs and manufactures medical-pharmaceutical combination devices. The firm commercializes implantable combination drug and device products focused on infection control including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs). Its AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including superbugs such as methicillin-resistant S. aureus (MRSA). The company was founded in 1998 by Satish Pulapura and Arikha Moses and is headquartered in Monmouth Junction, NJ. | Electronic Technology |
The Vertical Group LP
The Vertical Group LP Investment ManagersFinance The Vertical Group LP (TVG) is a venture capital firm founded in 1988 by Richard B. Emmitt. The firm is headquartered in Berkeley Heights, New Jersey. | Finance |
Helix Therapeutics, Inc.
Helix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Helix Therapeutics is a seed stage company based on technology discovered in the laboratory of Peter Glazer MD/PhD and licensed on a world wide, exclusive basis from Yale University. Targeted DNA modifications can be designed to: correct mutations, leading to restoration of normal function of key gene products, alter levels of gene expression, potentially turning genes on or off, functionally disrupt molecules, such as the CCR5 receptor, which mediates HIV entry into T cells. Through the use of SBIR grants and seed funding, it will advance preclinical projects targeting the human globin gene for applications on sickle cell anemia and beta-thalassemia, the CCR5 receptor for the HIV/AIDS population, and genetic mutations responsible for the liposomal storage disease, Gaucher's. Genetic alteration of stem cells has the potential to dramatically impact the efficacy of stem cell therapy for human disease. Due to the accessibility of HSC without bone marrow transplants, the company is currently focused on blood based genetic diseases. As advances in human stem cell biology are realized, however, it is possible to envision applications in a broad array of human genetic diseases. Moreover, because the DNA modifications introduced to stem cells are stable and heritable; this technology offers the hope of curing certain genetic diseases. Its approach does not rely on viral vectors and corrects the patients own cells, eliminating potential immune reactions. This approach is classified as Cellular Therapy, which provides another level of safety to the patient. | Health Technology |
Athena Ventures | Finance |
Galatea Surgical, Inc. |